Bio-Prodict is a Dutch biotechnology company revolutionizing protein engineering through its 3DM Engineering platform. This AI-driven solution integrates protein sequence, structure, and mutation data to predict and optimize protein functionality with unmatched precision. We aim to scale and commercialize 3DM Engineering, enabling faster, cost-effective development of enzymes, biopharmaceuticals, and bio medicines to address industry needs. Protein engineering is plagued by high costs, long timelines, and low success rates, limiting advancements in healthcare and sustainability. 3DM Engineering leverages 16 years of accumulated protein family data to identify critical hotspots and beneficial mutations, reducing costly trial-and-error approaches. Pilot studies have demonstrated its groundbreaking potential: a 98.5% reduction in time and costs compared to traditional methods, with proven applications such as enzymes showing over 11,000% activity improvement. The platforms unmatched predictive accuracy surpasses even major tech competitors, positioning Bio-Prodict as an industry leader. The initial target market is the protein engineering sector, valued at 2.54 billion in 2024 (CAGR 16.24%), with Bio-Prodicts 3DM Engineering capturing an estimated Serviceable Obtainable Market (SOM) of 125 million. Additionally, 3DM Engineering has the potential to revolutionize the pharmaceutical, enzyme, and synthesis markets, each with SOMs in the hundreds of millions. By providing tailored solutions and scalable innovation, 3DM Engineering addresses key industry needs and unlocks significant growth potential. To accelerate commercialization, Bio-Prodict seeks 5M in funding, with 2.5M from EICA grant and 2.5M equity from current and new investors. This funding will enable platform validation, marketing, and aggressive market entry to maintain its competitive edge. Bio-Prodicts experienced team is committed to advancing protein engineering, driving transformative impacts.